GLP-1 Drugs Reduce Cancer Risk

New research presented at the 2026 American Society of Clinical Oncology>>> Annual Meeting indicates that GLP-1 medications, widely used for weight loss and diabetes, may significantly reduce the risk of developing various cancers, including breast cancer. A retrospective analysis led by Elizabeth McDonald (radiologist)>>> of the University of Pennsylvania found that women taking GLP-1 drugs were approximately 30-35% less likely to develop breast cancer. These findings, also published in Journal of Clinical Oncology - Oncology Practice, suggest that GLP-1s may inhibit tumor growth through anti-inflammatory, metabolic, and epigenetic effects, beyond just weight loss. Other studies presented at the meeting by researchers like Colton Jones>>> and commented on by Marcin Chwistek>>> showed GLP-1 use was associated with lower odds of cancer progression, better survival, and improved responses to immunotherapies from companies like Merck & Co.>>> and Bristol Myers Squibb>>> across multiple tumor types. While observational, these studies highlight the potential for GLP-1 drugs, produced by companies such as Novo Nordisk>>> and Eli Lilly and Company>>>, as cancer prevention tools, prompting plans for prospective clinical trials.